Table 4.
Antitumor responses
| Response | Ipilimumab 3 mg/kg | Ipilimumab 10 mg/kg | Total | |||
|---|---|---|---|---|---|---|
| MM (n = 6) | NPC (n = 5) | MM (n = 0) | NPC (n = 14) | MM (n = 6) | NPC (n = 14) | |
| Best overall response, n (%) | ||||||
| CR | 0 | 0 | 0 | 0 | 0 | 0 |
| PR | 0 | 0 | 0 | 0 | 0 | 0 |
| SD | 0 | 1 (20) | 0 | 2 (14) | 0 | 3 (16) |
| PD | 5 (83) | 3 (60) | 0 | 11 (79) | 5 (83) | 14 (74) |
| NE | 1 (17) | 1 (20) | 0 | 1 (7) | 1 (17) | 2 (11) |
| ORR a , n (% [95% CI]) b | 0 | 0 | 0 | 0 | 0 | |
| DCR c , n (% [95% CI]) b | 0 | 1 (20) | 0 | 2 (14 [2–43]) | 0 | 3 (16 [3–40]) |
a
The proportion of patients whose best overall response is either a CR or a PR.
b
Confidence intervals were computed for cohorts of 10 patients or more only.
c
The proportion of patients with a CR or PR or who achieved SD.
Abbreviations: CI, confidence interval; CR, complete response; DCR, disease control rate; MM, malignant melanoma; NE, not evaluable; NPC, nasopharyngeal carcinoma; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.